Key Insights

Highlights

Success Rate

78% trial completion

Published Results

34 trials with published results (19%)

Research Maturity

90 completed trials (51% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

14.0%

25 terminated out of 178 trials

Success Rate

78.3%

-8.2% vs benchmark

Late-Stage Pipeline

6%

10 trials in Phase 3/4

Results Transparency

38%

34 of 90 completed with results

Key Signals

34 with results78% success25 terminated

Data Visualizations

Phase Distribution

142Total
Not Applicable (43)
Early P 1 (7)
P 1 (53)
P 2 (29)
P 3 (8)
P 4 (2)

Trial Status

Completed90
Recruiting33
Terminated25
Active Not Recruiting9
Withdrawn6
Not Yet Recruiting6

Trial Success Rate

78.3%

Benchmark: 86.5%

Based on 90 completed trials

Clinical Trials (178)

Showing 20 of 20 trials
NCT07416188Phase 1Recruiting

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

NCT07326566Phase 2Recruiting

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT07629089Phase 1Not Yet RecruitingPrimary

VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations

NCT07628647Not ApplicableNot Yet RecruitingPrimary

Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being

NCT05954858Not ApplicableRecruiting

Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma

NCT03630289Not ApplicableCompleted

Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM

NCT02861898Phase 1Recruiting

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

NCT04222309Phase 1Suspended

Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)

NCT03213002Phase 1Recruiting

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

NCT05979064Not ApplicableRecruiting

Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

NCT05271240Phase 3Recruiting

Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

NCT05116137Not ApplicableEnrolling By Invitation

The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors

NCT07374692Not ApplicableRecruiting

Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors

NCT06048094Phase 1Recruiting

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery

NCT05184790Recruiting

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

NCT05023434Not ApplicableRecruiting

A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors

NCT07210632Early Phase 1RecruitingPrimary

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

NCT07512154Not ApplicableRecruitingPrimary

Precision Radiotherapy Enabled by Molecular MRI

NCT03465618Phase 1Active Not RecruitingPrimary

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

NCT03170141Phase 1Enrolling By Invitation

Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme

Scroll to load more

Research Network

Activity Timeline